# Professor Aswath Damodaran examines the recent controversies surrounding pharmaceutical company Valeant

1 Faculty News March 24, 2016 ![Bloomberg logo](/sites/default/files/styles/246w/public/assets/images/bloomberg192x144.jpg?itok=yV529lwz)>

Excerpt from [Bloomberg](http://www.bloomberg.com/news/videos/2016-03-25/valuing-yahoo-and-valeant-what-d-you-miss-full-show-03-24) -- "I think Wall Street's so used to companies feeding analysts performer numbers, Pro Forma EBITDAs. 'Trust us. We're going to add this stuff back. Whether it is restructuring expenses, stock-based compensation, it's going to go away.' And analysts take companies at their word. Companies are going to keep feeding them numbers and Valeant in a sense has taken advantage of that. So when analysts complain about being taken to the cleaners, my response to them is you got what you deserved. Because I think they did exactly what analysts wanted them to do for a while and now it's blowing up in their faces."

[Watch the video](http://www.bloomberg.com/news/videos/2016-03-25/valuing-yahoo-and-valeant-what-d-you-miss-full-show-03-24)